cyclophosphamide + sulfamethoxazole + trimethoprim + etoposide + cytarabine

This combination refers to a multi-agent regimen consisting of five drugs: **cyclophosphamide** (an alkylating agent anti-cancer and immunosuppressive compound), **sulfamethoxazole** and **trimethoprim** (administered together as co-trimoxazole, an antibiotic for prophylaxis against infections), and **etoposide** with **cytarabine** (both cytotoxic chemotherapy agents). Such combinations may be employed in the treatment of various cancers including leukemia and lymphoma, with trimethoprim-sulfamethoxazole often included for infection prophylaxis during intense myelosuppressive regimens. Cyclophosphamide acts as an alkylating DNA-damaging agent, etoposide inhibits topoisomerase II leading to DNA breaks, cytarabine inhibits DNA synthesis as a nucleoside analog, and sulfamethoxazole-trimethoprim inhibits sequential steps in bacterial folate synthesis[1][2][7][6]. This specific combination as a single regimen is not a standard named protocol but reflects a set of agents commonly used together or in closely spaced phases.